Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...
The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.
With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials...
Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
The therapeutic benefits of many psychedelics have been clearly demonstrated through clinical trials, where the use of psilocybin-, ketamine-, and MDMA-assisted psychotherapy showed striking long-term improvements...
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.